Kiora Operating Margin from 2010 to 2024

KPRX Stock  USD 3.37  0.06  1.81%   
Kiora Pharmaceuticals Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin is likely to outpace its year average in 2024.
Check Kiora Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiora Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.2 K, Selling General Administrative of 4.8 M or Other Operating Expenses of 10.3 M, as well as many indicators such as Price To Sales Ratio of 16 K, Dividend Yield of 0.0 or PTB Ratio of 0.43. Kiora financial statements analysis is a perfect complement when working with Kiora Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kiora Pharmaceuticals Correlation against competitors.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Latest Kiora Pharmaceuticals' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Kiora Pharmaceuticals over the last few years. It is Kiora Pharmaceuticals' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (121.23) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Kiora Operating Margin Regression Statistics

Arithmetic Mean(249.65)
Coefficient Of Variation(135.97)
Mean Deviation308.27
Median(19.94)
Standard Deviation339.45
Sample Variance115,229
Range778
R-Value(0.82)
Mean Square Error40,130
R-Squared0.68
Significance0.0002
Slope(62.44)
Total Sum of Squares1.6M

Kiora Operating Margin History

2024 -741.93
2023 -780.98
2020 -679.11
2019 -2.61
2018 -6.56
2017 -35.73

About Kiora Pharmaceuticals Financial Statements

Kiora Pharmaceuticals investors use historical fundamental indicators, such as Kiora Pharmaceuticals' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kiora Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.